Yaacov Michlin joined Yissum in 2009 and serves as Yissum's President and Chief Executive Officer. Mr. Michlin has been leading and assisting pharmaceutical, hi-tech and biomedical companies (including Teva, Bioline, CBI and Brainsway) in various technology commercialization deals, licensing agreements, capital raising, mergers and acquisitions and joint venture collaborations. Mr. Michlin was involved in the foundation and strategic guidance of a few companies and ventures. Prior to joining Yissum Mr. Michlin was a partner at Tulchinsky Stern & Co. Law Offices. He holds a Bachelor of Law and Economics, cum laude, and a Master of Law degree, both from Bar-Ilan University, Israel, and an MBA, cum laude, from the Technion Israel Institute of Technology, Israel.
Mr. Cohen was appointed as Yissum’s CFO at the end of 2010. Prior to that, he served as Yissum’s controller since 2006. Previous experience includes the Finance department of the Jewish Agency and KPMG Somekh Chaikin, accounting firm. Mr. Cohen is a certified public accountant (Israel) and holds a BA degree in Business Management and Accounting and MBA (Cum Laude), both from the Israeli College of Management.
Dr. Keynan joined Yissum in 2008, with a strong background in scientific, industrial & business strategy. She joined Yissum from RadBioMed, one of Israel's leading biomedical incubators, where as project manager she was responsible for the deal flow, evaluation and management assistance to the CEO. Prior to that she worked at Quark Pharma, one of Israel's top biopharmaceutical companies, where she was the metabolic cell-based bioassay manager. Dr. Keynan holds a Ph.D. in biochemistry from the Hebrew University Hadassah Medical School in Jerusalem, and spent four years as a postdoctoral fellow in the biochemistry and molecular biology department at Leeds University, UK.
Ms. Markel joined Yissum in October 2008 from ProChon Biotech, where she headed the business development activities initiating and establishing joint projects with major companies in the field of sports medicine, in addition to negotiating distribution deals in Europe. Prior to that she served as a marketing strategy consultant to Invitrogen Ltd., a global provider and producer of advanced tools for biological research. She established the US sales and marketing operations of QuantomiX, an Israeli company, initiating the adoption of a cutting edge innovative technology in the field of electron microscopy by over 70 leading global pharmaceutical and biotechnology companies and major universities. Earlier in her career, she was a sales executive at Beckman Coulter Inc., a world leader in the production of scientific and diagnostic instrumentation for the life science markets, consulting on robotic systems for drug discovery. Ariela holds a B.Sc. (cum laude) and M.Sc. in biophysical chemistry from Ben Gurion University and an MBA from the joint international programme of the Kellogg School of Management at Northwestern University and Tel Aviv University.
Dr. Levy joined Yissum in 2011 and focuses on licensing agriculture and veterinary technologies. She brings strong scientific background along with experience is large scale projects from the municipal field. Dr. Levy holds a Ph.D. in Molecular Biology, M.Sc in Biotechnology and B.Sc. in Biochemistry and Food Sciences – all earned at the Hebrew University. She spent 3.5 years as a postdoctoral fellow in the Scholl of Medicine at UC Davis, CA, USA and another 2 years as a postdoctoral fellow in the Biological Chemistry Department, The Weizmann Institute of Science, Rehovot, Israel. Currently Dr. Levy serves as the Deputy Mayor of Oranit (voluntarily). She is also a board member of the Oranit Municipal Financial Corporation.
Dr. Goldwaser serves as VP, Head of Research Collaborations of Yissum & Business Development Manager of the Institute of Drug Research of the School of Pharmacy of the Hebrew University of Jerusalem (IDR). Dr. Goldwaser's career in the bio-pharmaceutical industry began over a decade ago, spanning executive and R&D management roles in the biotechnology, chemical and biological drug development markets. Dr. Goldwaser served as CEO of NasVax from its foundation in 2004 and later as president until April 2010. Dr. Goldwaser joined NasVax from Sol-Gel Technologies, where he served as CTO and Chief Biologist and R&D Project Manager overseeing the Company's experiments, worldwide collaborations, IP management, R&D and drug-candidate evaluation. Prior to that, Dr. Goldwaser worked as Lapid Pharmaceuticals' R&D Manager and Supervisor from 1999 through 2002. Dr. Goldwaser earned his Ph.D. degree in Biological Chemistry from the Weizmann Institute of Science, Rehovot, Israel, his M.Sc. in Medicinal Science from the Sackler School of Medicine, Tel Aviv, Israel, and a B.Sc. in Chemistry from the Hebrew University, Jerusalem, Israel. He is the co-owner of several registered patents of pharmacology and has authored numerous publications in this field.
Mr. Huberman joined Yissum in 2004, he is VP Business Development in the field of computer science and is further responsible for the technical infrastructure necessary to support Yissum’s business processes and application systems. In addition, he is also the IT Director of ITTN; the Israeli Technology Transfer Organization. Prior to joining Yissum, Mr. Huberman was the co-founder of Artigon, served as part of the R&D team at Orgenics (AMEX: IMA) and as the Head of IP and R&D at MedisEl (NASDAQ: MDTL). He holds an MSc. in structural biology and a BSc. in biology from the Hebrew University, a diploma in computer & electronics and has continued his MBA studies at the Hebrew University. He is also a certified Trainer of NLP from ABNLP.
Dr. Reichman is the licensing officer for chemical sciences-based technologies. He brings over 20 years of experience in senior management positions. Dr. Reichman was CEO of Polyheal Ltd., a medical device company and of Patholab Diagnostics Ltd. He is also the founder of a few high tech companies. Dr. Reichman served, in the past, as Sales & Marketing Manager at Sigma-Aldrich (NASDAQ: SIAL) and was the R&D Manager of Adumim Chemicals, a firm based on know-how developed at the Hebrew University, where he was involved in turn-key worldwide projects. Dr. Dov Reichman has a Ph.D. in chemistry from the Hebrew University of Jerusalem.
Mr. Trachtenberg joined Yissum in 2006 as general counsel, and is responsible for all legal aspects of Yissum’s activities, including technology licensing and intellectual property protection. An attorney with over 25 years of experience in the US and Israel, Mr Trachtenberg previously served as general counsel of Keryx Biopharmaceuticals (NASDAQ: KERX) and of Accent Software International He has a J.D. from New York University and a B.A. from the State University of New York at Binghamton.
Ms. Fredman joined Yissum in 2009 as Deputy General Counsel. Prior to joining Yissum, Ms. Fredman served in senior legal positions with several hi-tech and communications companies, including Bezeq International and Starhome (a Comverse affiliate). Ms. Fredman brings to Yissum over 20 years of experience drafting and negotiating complex agreements, managing intellectual property licensing and protection (particularly in the software and communications fields) and advising senior management on a broad range of strategic company issues. Ms. Fredman holds a bachelor of arts degree in economics and in education (Magna Cum Laude; Phi Beta Kappa) from Barnard College (affiliate of Columbia University) and a law degree (L.L.M.) from the Columbia University School of Law. She is a member of the American and Israeli Bar Associations.
Ms. Gallily joined Yissum in 2004 and oversees the professional aspects of Yissum's extensive patent portfolio and provide patent counselling and advice to support business activities. Ms Gallily’s 15 years of professional IP experience prior to joining Yissum include serving as in-house patent counsel at Keryx (NASDAQ: KERX) and as an attorney with a leading intellectual property firm for 15 years, where she focused on drafting and prosecuting patent applications in all fields of the life sciences. Ms Gallily holds an MSc in Physiology (neurobiology) from the Hebrew University and a diploma in organizational counselling from the College of Management.
Ms. Ben-Israel joined Yissum in 1988 and is responsible for the administration of its extensive portfolio of intellectual property from the initial invention disclosure by the researchers, through inter-institutional agreements, patent applications and prosecution and coordination of outside patent counsel activities. Prior to joining Yissum she has worked at Control Data Corporation Service Centre and at Luz Corporation in Jerusalem. Ms Ben Israel holds a BA degree in Humanities and East Asian Studies from the Hebrew University and Social Sciences at the University of Sao Paulo. She has studied Intellectual Property Law at The Felt Centre for Legal Studies at The Hebrew University.
Ms. Gavish-Fridman is responsible for overall marketing and PR activities at Yissum. Prior to joining Yissum in 2004, Ms Gavish-Fridman spent seven years as a producer at Israel’s Channel 2 television news, Associated Press Television, and Fox News. She subsequently worked in the business development area at several high-tech start-up companies and a business development consultancy. She holds a BA in Political Science and Literature, and an Executive MBA in Integrative Management, both from the Hebrew University of Jerusalem.
Mr. Fuchs joined Yissum in 1997 and is responsible for the strategic uses of information and competitive intelligence. He provides support to the Licensing, IP and Finance Departments, as well as to Yissum’s Management and Internal Counsel, with special focus on integrative analysis of Patents, Projects, and Agreements. Previously at Yissum Mr. Fuchs served as Project Manager and VP Licensing in the fields of agriculture, food and environment. Prior to joining Yissum, Mr. Fuchs had 15 years of extensive industrial experience in the fields of high vacuum process equipment, optoelectronics, water treatment and biological pest control.